Effect Of Multiple Dose PF-06700841 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids
NCT ID: NCT04267250
Last Updated: 2020-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
18 participants
INTERVENTIONAL
2020-08-24
2020-11-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study consists of a screening phase (up to 28 days prior to Day 1); two treatment periods during which participants are resident in the Clinical Research Unit (CRU) and a final follow-up telephone contact, which will be conducted after 28-35 following administration of the last dose.
Participants will be randomized to 1 of 2 treatment sequences. A total of 18 healthy female participants (9 in each treatment sequence) will be enrolled in the study. Each treatment sequence will consist of 2 periods in a single fixed sequence. Participants will be screened within 28 days of the first dose of investigational product. Participants will report to the Clinical Research Unit (CRU) the day prior to Day 1 dosing in Period 1 for both treatment sequences, and will report to the CRU the day prior to Day 1 dosing in Period 2 for Treatment Sequence 2. In Treatment Sequence 1, participants will remain in the CRU for up to 21 days and 20 nights. There will be no washout period in Treatment Sequence 1. In Treatment Sequence 2, participants will remain in the CRU for up to 22 days and 20 nights. Participants in treatment sequence 2 will have an outpatient washout period of at least 10 days between Period 1 and Period 2. A single administration of OC in the form of 1 PORTIA or equivalent tablet will be administered in one of the two periods (reference treatment) and in the alternative treatment period, daily doses of 60 mg PF-06700841 will be administered for 13 days with a single dose of OC being administered on Day 10. PK (AUCinf, Cmax, AUClast, Tmax and t½) of OC will then be assessed at pre OC dose and over 96 hours, post OC dosing.
Safety assessments will be conducted at the CRU.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence 1
In sequence 1, period 1, participants will be dosed with a single administration of oral contraceptive (OC). Participants will continue directly into period 2 where they will receive PF-06700841 PO for 13 days with a single dose of OC administered on the morning of day 10.
PF-06700841
60 mg by mouth (PO) once daily (QD).
Ethinyl estradiol (EE) and levonorgestrel (LN)
Oral tablet containing 30 mcg EE and 150 mcg LN.
Sequence 2
In sequence 2, period 1, participants will receive PF-06700841 PO for 13 days with a single dose of OC administered on the morning of day 10. After a wash-out period of at least 10 days, participants will continue into period 2 where they will receive an additional single dose of OC.
PF-06700841
60 mg by mouth (PO) once daily (QD).
Ethinyl estradiol (EE) and levonorgestrel (LN)
Oral tablet containing 30 mcg EE and 150 mcg LN.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PF-06700841
60 mg by mouth (PO) once daily (QD).
Ethinyl estradiol (EE) and levonorgestrel (LN)
Oral tablet containing 30 mcg EE and 150 mcg LN.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Not of childbearing potential
* Body mass index of 17.5-30.5 kg/m2
* Body weight \> 50 kg
* Capable of giving signed informed consent
Exclusion Criteria
* Any condition affecting drug absorption
* Participants who have experienced major trauma or surgery in the 3 months prior to baseline
* Participants in imminent need for surgery
* Use of prescription or non-prescription drugs within 7 days or 5 half-lives prior to dosing
* Previous administration with an investigational drug within 30 days or 5 half-lives prior to dosing
* A positive urine drug test
* Hypertension
* ECG anomalies
* Significant laboratory anomalies
* History of drug abuse with less than 6 months of abstinence prior to the baseline visit
* History of alcohol abuse within 6 months of screening
* History of nicotine use within 30 days of baseline visit
* Any contraindications to OC
* History of discontinued use of OC for medical reasons
* Febrile illness within 5 days prior to dosing
* Vaccination with live or attenuated virus or live viral components within 6 weeks prior to dosing
* History of major organ transplant
* History of severe allergic or anaphylactic reaction to kinase inhibitors
* have donated blood of 500mL or more within 60 days prior to dosing
18 Years
60 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Quotient Sciences Screening Office
Coral Gables, Florida, United States
Quotient Sciences-Miami
Miami, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Oral Contraceptive DDI
Identifier Type: OTHER
Identifier Source: secondary_id
B7931018
Identifier Type: -
Identifier Source: org_study_id